1154-97 Electrocardiogram morphology predictors of pharmacologic termination of ventricular tachycardia  by Somberg, John C et al.
JACC March 3, 2004 ABSTRACTS - Myocardial Ischemia and Infarction  301A
M
yocardial Ischem
ia and Infarction
23 patients (53.4%; 95% CI 38.6%-68.4%). This result is consistent with two prior studies
of PEA utilizing transesophageal echocardiography. CONCLUSION: The 2 MHz audible
Doppler provides rapid, accurate and non-invasive evidence of cardiac contractility and
thus occult blood flow in a substantial proportion of cardiac arrest patients with suspected
PEA. Developing a "Suspected PEA With Occult Blood Flow" algorithm may lead to more
appropriate treatment and improved survival.
1154-94 Effects of Incomplete Chest Wall Decompression During 
Cardiopulmonary Resuscitation on Coronary and 
Cerebral Perfusion Pressures in a Porcine Model of 
Cardiac Arrest
Demetris Yannopoulos, Gardar Sigurdsson, Scott McKnite, David Benditt, Tom 
Aufderheide, Ron Pirrallo, Terry Prove, Todd Zielinski, Keith G. Lurie, University of 
Minnesota, Minneapolis, MN, Medical College of Wisconsin, Madisson, WI
BACKGROUND: Recent data suggest that generation of negative intra-thoracic pressure
during the decompression phase of CPR improves hemodynamics, organ perfusion and
survival. We hypothesize that incomplete chest wall recoil during the decompression
phase of standard CPR increases intrathoracic pressures and intracranial pressures
resulting in a decrease in venous return in the chest cavity and therefore a decrease in
coronary perfusion pressure, an increase in intracranial pressure and a decrease in cere-
bral perfusion pressures.
METHODS: 9 pigs in ventricular fibrillation for 6 min, were treated with an automated
compression/decompression device with compressions at 100/min and a depth of 25% of
the antero-postero diameter and a compression to ventilation ratio of 15:2 with 100%
decompression (standard CPR) for 3 min. Compression depth was reduced to 75% of
complete decompression for 1 min of CPR and then restored for another 1 min of CPR to
100% decompression. Coronary perfusion pressure (CPP) was calculated as the dias-
tolic (aortic – right atrial (RA) pressure). Cerebral perfusion pressure (CePP) was calcu-
lated as diastolic (Aortic minus intracranial pressure). Unpaired t-test was used for
statistical analysis. All pressures expressed as mmHg.
Results: With 100% - 75% - 100% chest wall recoil, the CPP was 23.5 ± 2.0, 15.0±1,
15.5±1 (P<0.01); CePP was 8.5±3.4,-0.9 ±2.4, 1.9±3 (P=0.03); diastolic aortic pressure
was 26.5±2.5, 19.3±2, 18.5±1.9; intracranial pressure during decompression was 18.1±
2.4, 20.2±2, 16.6± 2.3; RA diastolic pressure 3±1.8, 4.2±1.7, 3.17±1.4; and MAP was
41.6±3.3, 34.2±2.7, 38.6±2.9.
CONCLUSIONS: Incomplete chest wall recoil during the decompression phase of CPR
significantly decreased coronary and cerebral perfusion pressures and increased intrac-
ranial pressures.
1154-95 Chest Compression Device Improves Blood Flow in 
Cerebrum and Myocardium Achieving Neurologically 
Intact Survival in a Porcine Model of Prolonged Cardiac 
Arrest
Fumiaki Ikeno, Jennifer Lyons, Hideaki Kaneda, Yoichiro Hongo, Sascha Emami, 
Christine Nolasco, Mehrdad Rezaee, Stanford University, Palo Alto, CA
Background-The insufficient blood flow to the heart and brain generated by chest com-
pression affects survival after sudden death. In order to improve blood flow, an auto-
mated, self-adjusting, electromechanical device (AutoPulse) that utilizes a load-
distributing band to compress the anterior chest has been developed. In this study, blood
flow generated by CPR with AutoPulse (A-CPR) was compared to conventional CPR (C-
CPR) and the impact on neurological intact survival after prolonged cardiac arrest was
determined.
Methods and Results-8 minutes after induction of untreated ventricular fibrillation, 32 pigs
were randomized to either A-CPR (n=22) or C-CPR (n=10) for 4 minutes, followed by
resuscitation protocol with ventilation, defibrillation, and intravenous epinephrine.
Regional blood flows in heart and cerebrum were determined using neutron-activated
microspheres. A-CPR improved regional myocardial flow by 58 fold and cerebral flow by
13 fold as compared to C-CPR. 16/22 in A-CPR regained spontaneous circulation and
survived; 14/16 had normal cerebral performance category (CPC=1) at 24 hours (2/16
exhibited mild neurological dysfunction, CPC=2). None of the C-CPR subjects returned
to spontaneous circulation.
Conclusion-Improved hemodynamics with the AutoPulse CPR results in neurologically
intact survival in this model of prolonged cardiac arrest.
1154-96 A New Method for Detecting Cardiogenic Pulmonary 
Edema Before the Appearance of Clinical Signs and for 
the Evaluation of Treatment Efficacy
Michael Shochat, Simcha Meizel, Pavel Rabinivich, Benny Peled, Avraham Shotan, Hillel 
Jaffe, Hadera, Israel
The aim of this study was to investigate whether patients with heart disease can be effec-
tively monitored by a new index, ITI (internal thoracic impedance), so that evolving car-
diogenic pulmonary edema (CPE) can be detected at its pre-clinical stage. If reliable,
such monitoring could enable the early treatment of CPE, enhance its efficacy, and pos-
sibly abort the process of worsening pulmonary congestion. A new impedance monitor
(RS-205) was used in this study. This monitor measures ITI by subtracting the skin-elec-
trode contact impedance from total transthoracic impedance. The clinical onset of CPE
was determined according to accepted clinical and radiographic criteria. ITI of the right
side of the chest was measured every 30 minutes in 264 consecutive patients hospital-
ized for an acute coronary syndrome. In all 264 patients that comprised study population
monitoring was initiated when clinical symptoms and signs of CPE were absent. 38 of
these patients developed CPE during monitoring. In all 38 patients, ITI decreased by
more than 12% from the initial value 30 minutes and in 23 of these patients it occurred
one hour before the clinical onset of CPE, respectively (p<0.001). In light of these find-
ings therapy was initiated in 4 patients when an ITI decrease of 11-12% from initial value
was recorded. In these 4 patients, clinical CPE did not develop and ITI returned to initial
value after treatment. In contrast, ITI did not decrease by more than 10% in any of the
remaining 222 patients who did not develop CPE. Further evaluation of the impact of ITI
monitoring on the clinical course of patients at risk to develop CPE seems warranted.
Conclusion: TI monitoring was found to be an accurate, practical and reliable method to
detect CPE at its pre-clinical stage and to gauge of the effectiveness of the treatment.
The preliminary data in four patients show that treatment of CPE in its pre-clinical stage
may abort CPE evolution.
1154-97 Electrocardiogram Morphology Predictors of 
Pharmacologic Termination of Ventricular Tachycardia
John C. Somberg, Charles I. Haffajee, Sandor Timar, Steven J. Bailin, Istvan Sarosi, 
Walter P. Paladino, Ferenc Lakatos, Nicholas Z. Kerin, Jeno Tarjan, Jozsef Borbola, 
Janos Molnar, and The Amio-Aqueous Investigators, Rush University, Chicago, IL
Background: Pharmacologic termination of ventricular tachycardia (VT) is variable with
different degrees of efficacy with different agents. This study was undertaken to deter-
mine if there are morphologic characteristics of VT that may predict drug efficacy.
Methods: 172 patients with sustained VT were randomized to receive either a 150 mg
bolus of a new formulation of intravenous amiodarone (A) or a bolus of 100 mg lidocaine
(L). If the first bolus failed to terminate the VT, a second bolus was administered. If the VT
persisted, electroshock was delivered. In each patient, an electrocardiogram (EKG) was
recorded before drug administration during VT and was analyzed for VT morphology:
polymorphic vs monomorphic VT, QRS width, QRS amplitude, as well as ventricular rate.
Multivariate analysis (ANOVA) was performed to assess the possible predictors of VT ter-
mination.
Results: Of the 172 patients, 29 had shock resistant VT, 143 had sustained hemody-
namically unstable VT. Of the 94 patients who received A, 85 had monomorphic VT with
50 terminating pharmacologically (59%) and 9 had polymorphic VT with a 33% termina-
tion (NS). Of the 78 patient who received L, 74 had monomorphic VT with 44 (59%) phar-
macologic VT termination and 4 had polymorphic VT with a 25% termination (p=0.05).
For shock resistant monomorphic VT, the cumulative VT termination was 75% with A vs.
33% with L (p<0.05) and for shock resistant polymorphic VT 83% with A vs. 0% with L
(p<0.05). The QRS was narrower in converters vs. non converters (141±27 ms vs.
175±54 ms, p<0.001). There was a trend of slower VT rate between converters vs. non
converters (175±31 vs. 182±35 beats/minute, NS), but there was no difference in VT
amplitude. In the 172 patients, the cumulative VT terminations (pharmacologic and elec-
troshock) for A vs. L were 91% vs. 85% in monomorphic VT (NS) and 89% vs. 25% in
polymorphic VT (p<0.01).
Conclusions: Amiodarone was more effective than L in converting VT in patients with
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polymorphic VT, while A and L were equally effective in hemodynamically unstable sus-
tained monomorphic VT. Patients with polymorphic VT and a wide QRS were more likely
to convert with A while L was ineffective in these patients.
1154-98 Ventricular Fibrillation Triggered by Thoracic 
Compression During Out-of-Hospital Cardiac Arrest 
Resuscitation in the Piacenza Vita Project
Alessandro Capucci, Daniela Aschieri, Simona Bennati, Massimo Piepoli, Giovanni 
Quinto Villani, Giovanni Quinto Villani, Maurizio Arvedi, Gust Bardy, G.da Saliceto 
Hospital, Piacenza, Italy
Background. Decreasing the delay to defibrillation by introducing the automated external
defibrillators (AEDs) has increased the number of potential first responders. The role of
CPR training in lay first responders is still debated and data on the benefit of sterno-tho-
racic compression when a spontaneous cardiac rhythm (SCR) has been recovered are
scanty. We examined whether: 1) CPR may influence survival ; 2) sterno-thoracic com-
pression after recovery of SCR has benefic effects.
Methods. Piacenza Progetto Vita (PPV) involves 2631 lay volunteers trained by a 4 hour
course to intervene only with the AED in cases of suspected sudden cardiac arrest
(SCA). 135 consecutive cases of SCA with ventricular fibrillation (VF) were treated. Sur-
vival rate was evaluated. and EKG tracing was analyzed where early defibrillation per-
formed by lay volunteers was followed by traditional CPR by EMS.
Results. 77/135 cases were treated by PPV volunteers and 58/135 by EMS. Survival rate
from shockable rhythm was 32% (25/77) in PPV group vs 18% (11/58) in EMS group (p <
0.05). The EKG analysis of 25 survivors of group PPV showed: 1) 19 pts had more than
1 episode of VF (1.9 VF/pt) for a total of 36 episodes; 2) the time from effective shock and
the first spontaneous QRS was 16.2+17.1 sec (median 3-48 sec); 3) the mean rate of
first SCR was 34 + 12 bpm; 4) sinus rhythm was present as first SCR after 12 (31%) ven-
tricular fibrillation; 4) sinus rhythm compared earlier than wide QRS (4+2 sec vs 28+12
sec, p < 0.001); 5) chest compression was performed in 22 cases irrespective of the
presence of SCR. In 14 cases sterno-thoracic compression was directly associated with
VF induction;
Conclusion. Defibrillation alone increase survival in out of hospital cardiac . Post defibril-
lation sterno-thoracic compression may trigger ventricular fibrillation. Sterno thoracic
compression may be delayed of almost 30-60 seconds when spontaneous rhythm has
been recovered.
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861-1 Direct, Selective, Factor Xa Inhibition in Patients With 
Non-ST Elevation Acute Coronary Syndromes From the 
United States, Canada, and Japan: Results of the 
XaNADU-ACS Trial
John H. Alexander, Hongqiu Yang, Richard C. Becker, Kazuhisa Kodama, Christopher K. 
Dyke, Shaun G. Goodman, Neal S. Kleiman, Judith S. Hochman, Peter B. Berger, Eric A. 
Cohen, Michael Lincoff, Edwin G. Bovill, Chuichi Kawai, Paul W. Armstrong, Robert A. 
Harrington, Duke University Medical Center, Durham, NC
Background: New anticoagulants are needed for patients with non-ST elevation acute
coronary syndromes (ACS). We investigated the efficacy and safety of a novel direct,
selective, factor Xa inhibitor, DX-9065a (Daiichi Pharma. LTD, Inc.) compared to unfrac-
tionated heparin (UFH).
Methods: Patients with ACS from the US (n=313), Canada (n=45), and Japan (n=47)
were randomized 1:1:1 to one of two blinded regimens of DX-9065a and UFH placebo or
to weight adjusted UFH and DX-9065a placebo. DX-9065a was administered as a bolus,
3 hour rapid infusion, and maintenance infusion of 0.025 mg/kg, 0.04 mg/kg/hr; and
0.012 mg/kg/hr in one regimen and 0.05 mg/kg, 0.08 mg/kg/hr, and 0.024 mg/kg/hr in the
other. The primary endpoint was death, MI, urgent revascularization, or recurrent
ischemia on continuous ST-segment monitoring. Projected death, MI, urgent revascular-
ization and recurrent ischemia rates were 3.0%, 9.0%, 4.5%, 30.0% for UFH.
Results: Enrollment was completed on September 8, 2003. Preliminary results are avail-
able on 339 patients. The trial remains blinded so aggregate baseline, in-hospital man-
agement, and outcome data by country are presented. *includes CABG.
Conclusions: Direct selective, factor Xa inhibition may be an attractive alternative anti-
coagulant in patients with ACS. This is the first randomized experience with DX-9065a in
ACS and will provide the basis for further phase 3 investigation. Complete efficacy and
safety data from XaNADU ACS will be available at the ACC.
4:15 p.m.
861-2 Enoxaparin Versus Unfractionated Heparin in Patients 
Treated With Tirofiban, Aspirin, and an Early 
Conservation Initial Management Strategy: Results 
From the A Phase of the A to Z Trial
James A. de Lemos, Michael A. Blazing, Harvey D. White, Keith A. Fox, Peter M. 
DiBattiste, Joanne Palmisano, David W. Bilheimer, William E. Brady, Laura H. Gardner, 
Karen E. Ramsey, Eldrin F. Lewis, Marc A. Pfeffer, Robert M. Califf, Eugene Braunwald, 
University of Texas Southwestern Medical Center, Dallas, TX, Duke University Medical 
Center, Durham, NC
Introduction: In high-risk patients with non-ST elevation acute coronary syndromes
(ACS), enoxaparin (enox) is generally preferred to unfractionated heparin (UFH). How-
ever, few data are available comparing enox with UFH in patients receiving concomitant
glycoprotein IIb/IIIa inhibitors.
Methods: The A phase of the A to Z trial randomized 3987 patients with non ST eleva-
tion ACS to receive either enox (n= 2026) or UFH (n= 1961) in combination with aspirin
and tirofiban. Inclusion required either ST depression or cardiac biomarker elevation.
While the selection of an early management strategy (invasive or conservative) was at
the discretion of the local investigator, investigators were asked to designate their intent
for an invasive or conservative strategy at the time of randomization. Comparison of enox
with UFH in the subgroup of patients for whom an invasive strategy was planned is lim-
ited by the protocol design: crossover from enox to UFH was permitted at the time of
catheterization. In contrast, in subjects for whom an early conservative strategy was
planned, crossover was rare (4.4%), allowing a more direct comparison of the two anti-
thrombotic strategies. The primary endpoint was a composite of all-cause mortality, new
MI, and documented refractory ischemia within 7 days of randomization. Independent
subjective and objective assessments of bleeding using TIMI definitions were collected.
Results: A conservative strategy was planned in 872 patients (44.6%) randomized to
UFH and 906 patients (44.8%) randomized to enox. Among patients with a planned con-
servative strategy, the primary endpoint occurred in 10.6% of patients randomized to
UFH and 7.7% of patients randomized to enox (HR 0.73; 95% CI 0.53-0.99). In this sub-
group, the combined rate of TIMI major, minor, or loss no-site bleeding was 1.3% in
patients treated with UFH and 1.8% in those treated with enox (p=0.44).
Conclusions: When a conservative approach to catheterization and PCI was planned
for patients receiving tirofiban and aspirin, enoxaparin was associated with superior effi-
cacy and similar bleeding vs UFH.
Preliminary Results
United States
n=248
Canada
n=45
Japan
n=47
Overall
n=399
Age (yrs) 56 (49,66) 64 (56,71) 68 (60,72) 59 (51,69)
Female (%) 30 23 38 30
Weight (kg) 87 (75,100) 83 (70,94) 60 (56,69) 82 (69,96)
Diabetes (%) 25 16 21 24
Hypertension (%) 53 59 53 54
Prior CHF (%) 7 7 4 6
Prior MI (%) 28 32 11 26
Aspirin (%) 92 82 96 91
B-Blocker (%) 83 90 32 76
ACE-I (%) 61 79 21 57
Lipid Rx (%) 80 79 30 72
GP IIb/IIIa (%) 71 47 0 57
Cath (%) 98 93 100 98
PCI (%) 54 43 62 54
CABG (%) 19 27 2 18
Death (%) 2 2 0 2
MI (%) 9 9 13 9
Urgent Revasc (%) 4 14 13 6
ST-monitor ischemia (%) 24 25 24 24
Composite (%) 25 32 36 28
TIMI Major Bleeding (%)* 14 25 2 14
TIMI Minor Bleeding (%) 7 5 7 6
Any Bleeding (%)* 33 57 30 36
Transfusion (%)* 12 21 4 12
